First patients to receive experimental cancer drug in groundbreaking trial
NCT ID NCT07159126
Summary
This is the first study in humans testing a new cancer drug called DS3610a. It aims to find a safe and tolerable dose for people with advanced solid tumors that have stopped responding to standard treatments. The study will enroll about 70 participants to monitor side effects and see if the drug shows early signs of fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center Hospital
RECRUITINGChūōku, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, 277-8577, Japan
Conditions
Explore the condition pages connected to this study.